Sweden's Alligator Bioscience Q4 net loss widens

Alligator Bioscience AB

12/02/2026 07:14

Overview

Sweden biotech firm reported Q4 net loss

Company completed rights issue, raising SEK 91 mln to strengthen financial position

U.S. patent granted for ATOR-4066, supporting long-term pipeline value

Outlook

Company focuses on advancing mitazalimab towards registrational trials

Alligator emphasizes operational discipline amid challenging funding environment

Rights issue may provide further funding flexibility in 2026

Result Drivers

MITAZALIMAB ADVANCEMENT - Co focused on advancing mitazalimab towards registrational trials, supported by new scientific publications and presentations

FINANCIAL STRENGTHENING - Rights issue completed, raising SEK 91 mln to support mitazalimab development and financial flexibility

INTELLECTUAL PROPERTY - U.S. patent granted for ATOR-4066, reinforcing long-term pipeline value

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
-SEK 0.66
Q4 Net Income
-SEK 29 mln
Q4 EBIT
-SEK 22.50 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Alligator Bioscience AB is SEK5.33, about 2,580.4% above its February 11 closing price of SEK0.20

Press Release: ID:nMFN5Z84zK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)